韓霆博士
- 基本信息
- 教育經(jīng)歷
- 工作經(jīng)歷
- 研究概述
- 發(fā)表文章
韓霆博士
北京生命科學研究所高級研究員
Ting Han, Ph.D. Associate Investigator, NIBS, Beijing, China
Phone: 86-10-80726688
Fax: 86-10-80726689
E-mail:hanting@nibs.ac.cn
教育經(jīng)歷
Education
2006年 清華大學 生物學學士學位
B.S.
Biology, Tsinghua University, Beijing, China
2013年 美國密西根大學細胞和發(fā)育生物學博士
Ph.D. Cell and Developmental Biology, University of Michigan, Ann Arbor,
MI, USA
工作經(jīng)歷
Professional Experience
2025 - 北京生命科學研究所高級研究員
Associate Investigator, National Institute
of Biological Sciences, Beijing, China
2017 - 2024 北京生命科學研究所研究員
Assistant Investigator, National Institute of Biological Sciences, Beijing, China
2013 - 2017 美國德克薩斯大學西南醫(yī)學中心博士后
Postdoctoral Research Fellow, UT Southwestern
Medical Center, Dallas, USA
研究概述
Research Description:
我們實驗室的研究聚焦于化學生物學和癌癥生物學兩個互補領域，交匯點在于開發(fā)創(chuàng)新的癌癥治療策略。我們的目標是應對生物醫(yī)學中的兩大核心挑戰(zhàn)：（1）缺乏通用方法來有效調(diào)控大多數(shù)致病蛋白；（2）可支持未來治療創(chuàng)新的新靶點逐漸枯竭。在過去的幾年中，我們通過“化學驅(qū)動”和“生物驅(qū)動”兩種方法，在這些領域取得了進展?！盎瘜W驅(qū)動”的方法以基于表型的高通量篩選為起點，尋找具有選擇性抗癌活性的小分子，并進一步解析其作用機制?！吧矧?qū)動”的方法通過體內(nèi)CRISPR篩選，揭示腫瘤內(nèi)在的免疫逃逸機制。這些研究不僅深化了我們對癌癥生物學的認識，還提供了開發(fā)抗癌療法的新靶點和化學起點。
The research in my lab is focused on two complementary areas at the forefront of chemical biology and cancer biology that converge at new therapeutic strategies for cancer treatment. We organize our efforts to tackle two challenges in biomedicine: (1) the lack of a general strategy to therapeutically modulate the majority of disease-causing proteins; (2) the exhaustion of new targets that can fuel future therapeutic innovations. Over the past several years, we have made considerable progress in these two areas by taking either a chemistry-first or a biology-first approach. The chemistry-first approach starts with phenotype-based high-throughput screening of small molecules with selective anticancer activities followed by the elucidation of their mechanisms of action. The biology-first approach employs in vivo CRISPR screening to identify tumor-intrinsic mechanisms of immune evasion. Such efforts not only improve our understanding of cancer biology but also provide novel targets and chemical starting points for developing anticancer therapy.
發(fā)表論文
Publications:
1. Lu, P., Cheng, Y., Xue, L., Ren, X., …, Huang, N.*, Han, T.* (2024). Selective degradation of multimeric proteins by TRIM21-based molecular glue and PROTAC degraders. Cell, 2024 Dec 12;187(25):7126-7142.e20.
2. Wang, L., Han, T.* (2024). Pharmacologic induction of ERα SUMOylation disrupt its chromatin binding. ACS Chemical Biology, 2024 Nov 15;19(11):2383-2392.
3. Xu, X., Lu, Y., Cao, L., Miao, Y., Li, Y., Cui, Y., Han, T.* (2024). Tumor-intrinsic P2RY6 drives immunosuppression by enhancing PGE2 production. Cell Rep, 43(7):114469.
4. Cao, Z., Sun, W., Zhang, J., …, Han, T., Li, C. (2024). Total syntheses of (-)-macrocalyxoformins A and B and (-)-ludongnin C. Nature Communications, 15(1):6052.
5. Li, S., Han, T.* (2024). Frequent loss of FAM126A expression in colorectal cancer results in selective FAM126B dependency. iScience, 27(5):109646.
6. Cui, Y., Miao, Y., …, Xu, M.*, Han, T.* (2023). Activation of melanocortin-1 receptor signaling in melanoma cells impairs T cell infiltration to dampen antitumor immunity. Nature Communications, 14(1):5740.
7. Tao, Z., Cui, Y., Xu, X., Han, T.* (2022). FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma. Proc Natl Acad Sci U S A, 119(40):e2208844119
8. Yuan, H., Zhu, Y., Cheng, Y., Hou, J., Jin, F., Li, M., . . . Han, T.* (2022). BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma. J Bio Chem, 298(11):102555
9. Lv, L., Chen, P., Cao, L., Li, Y., Zeng, Z., Cui, Y., . . . Han, T. * (2020). Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger Cyclin K degradation. Elife, 9. doi:10.7554/eLife.59994
10. Zeng, Z., & Han, T. * (2020). Discovering Nature's super glue. Nat Chem Biol. doi:10.1038/s41589-020-0586-x
11. Fuller, G. G., Han, T., Freeberg, M. A., Moresco, J. J., Ghanbari Niaki, A., Roach, N. P., . . . Kim, J. K. (2020). RNA promotes phase separation of glycolysis enzymes into yeast G bodies in hypoxia. Elife, 9. doi:10.7554/eLife.48480
12. Han, T., & Nijhawan, D. (2019). Exome Sequencing of Drug-Resistant Clones for Target Identification. Methods Mol Biol, 1888, 175-187. doi:10.1007/978-1-4939-8891-4_10
13. Zhang, J., Li, Z., Zhuo, J., Cui, Y., Han, T., & Li, C. (2019). Tandem Decarboxylative Cyclization/Alkenylation Strategy for Total Syntheses of (+)-Longirabdiol, (-)-Longirabdolactone, and (-)-Effusin. J Am Chem Soc, 141(20), 8372-8380. doi:10.1021/jacs.9b03978
14. Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T. C., . . . Nijhawan, D. (2017). Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. Science, 356(6336). doi:10.1126/science.aal3755
15. Han, T., Goralski, M., Capota, E., Padrick, S. B., Kim, J., Xie, Y., & Nijhawan, D. (2016). The antitumor toxin CD437 is a direct inhibitor of DNA polymerase alpha. Nat Chem Biol, 12(7), 511-515. doi:10.1038/nchembio.2082
16. Han, T., & Kim, J. K. (2016). Mapping the Transcriptome-Wide Landscape of RBP Binding Sites Using gPAR-CLIP-seq: Experimental Procedures. Methods Mol Biol, 1361, 77-90. doi:10.1007/978-1-4939-3079-1_5
17. Alessi, A. F., Khivansara, V., Han, T., Freeberg, M. A., Moresco, J. J., Tu, P. G., . . . Kim, J. K. (2015). Casein kinase II promotes target silencing by miRISC through direct phosphorylation of the DEAD-box RNA helicase CGH-1. Proc Natl Acad Sci U S A, 112(52), E7213-7222. doi:10.1073/pnas.1509499112
18. Han, T., & Kim, J. K. (2014). Driving glioblastoma growth by alternative polyadenylation. Cell Res, 24(9), 1023-1024. doi:10.1038/cr.2014.88
19. Wang, G., Han, T., Nijhawan, D., Theodoropoulos, P., Naidoo, J., Yadavalli, S., . . . McKnight, S. L. (2014). P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage. Cell, 158(6), 1324-1334.
20. Freeberg, M. A., Han, T., Moresco, J. J., Kong, A., Yang, Y. C., Lu, Z. J., . . . Kim, J. K. (2013). Pervasive and dynamic protein binding sites of the mRNA transcriptome in Saccharomyces cerevisiae. Genome Biol, 14(2), R13. doi:10.1186/gb-2013-14-2-r13
21. Billi, A. C., Alessi, A. F., Khivansara, V., Han, T., Freeberg, M., Mitani, S., & Kim, J. K. (2012). The Caenorhabditis elegans HEN1 ortholog, HENN-1, methylates and stabilizes select subclasses of germline small RNAs. PLoS Genet, 8(4), e1002617. doi:10.1371/journal.pgen.1002617
22. Gerstein, M. B., Lu, Z. J., Van Nostrand, E. L., Cheng, C., Arshinoff, B. I., Liu, T., . . . Waterston, R. H. (2010). Integrative analysis of the Caenorhabditis elegans genome by the modENCODE project. Science, 330(6012), 1775-1787. doi:10.1126/science.1196914
23. Mangone, M., Manoharan, A. P., Thierry-Mieg, D., Thierry-Mieg, J., Han, T., Mackowiak, S. D., . . . Kim, J. K. (2010). The landscape of C. elegans 3'UTRs. Science, 329(5990), 432-435. doi:10.1126/science.1191244
24. Han, T., Manoharan, A. P., Harkins, T. T., Bouffard, P., Fitzpatrick, C., Chu, D. S., . . . Kim, J. K. (2009). 26G endo-siRNAs regulate spermatogenic and zygotic gene expression in Caenorhabditis elegans. Proc Natl Acad Sci U S A, 106(44), 18674-18679. doi:10.1073/pnas.0906378106
25. Friedlander, M. R., Adamidi, C., Han, T., Lebedeva, S., Isenbarger, T. A., Hirst, M., . . . Rajewsky, N. (2009). High-resolution profiling and discovery of planarian small RNAs. Proc Natl Acad Sci U S A, 106(28), 11546-11551. doi:10.1073/pnas.0905222106
26. Li, S., Liu, C., Li, N., Hao, T., Han, T., Hill, D. E., . . . Lin, J. D. (2008). Genome-wide coactivation analysis of PGC-1alpha identifies BAF60a as a regulator of hepatic lipid metabolism. Cell Metab, 8(2), 105-117. doi:10.1016/j.cmet.2008.06.013
27. Zhao, W., Feng, D., Sun, S., Han, T., & Sui, S. (2010). The anti-viral protein of trichosanthin penetrates into human immunodeficiency virus type 1. Acta Biochim Biophys Sin (Shanghai), 42(2), 91-97.
